BR0210561A - Composição de liberação controlada, medicamento, droga para a prevenção ou cura para doenças, ou um agente contraceptivo, agente para a prevenção da recorrência de câncer de mama após a operação de câncer de mama pré-menopausal, e, métodos de prevenção ou de cura de doenças, ou um método de contracepção, de produção da composição de liberação controlada, e para a prevenção da recorrência de câncer de mama após a operação de câncer de mama pré-menopausal - Google Patents

Composição de liberação controlada, medicamento, droga para a prevenção ou cura para doenças, ou um agente contraceptivo, agente para a prevenção da recorrência de câncer de mama após a operação de câncer de mama pré-menopausal, e, métodos de prevenção ou de cura de doenças, ou um método de contracepção, de produção da composição de liberação controlada, e para a prevenção da recorrência de câncer de mama após a operação de câncer de mama pré-menopausal

Info

Publication number
BR0210561A
BR0210561A BR0210561-6A BRPI0210561A BR0210561A BR 0210561 A BR0210561 A BR 0210561A BR PI0210561 A BRPI0210561 A BR PI0210561A BR 0210561 A BR0210561 A BR 0210561A
Authority
BR
Brazil
Prior art keywords
breast cancer
prevention
controlled release
cure
release composition
Prior art date
Application number
BR0210561-6A
Other languages
English (en)
Inventor
Kazumichi Yamamoto
Akiko Yamada
Yoshio Hata
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26617910&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0210561(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of BR0210561A publication Critical patent/BR0210561A/pt
Publication of BRPI0210561B1 publication Critical patent/BRPI0210561B1/pt
Publication of BRPI0210561B8 publication Critical patent/BRPI0210561B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Abstract

"COMPOSIçãO DE LIBERAçãO CONTROLADA, MEDICAMENTO, DROGA PARA A PREVENçãO OU CURA PARA DOENçAS, OU UM AGENTE CONTRACEPTIVO, AGENTE PARA A PREVENçãO DA RECORRêNCIA DE CâNCER DE MAMA APóS A OPERAçãO DE CâNCER DE MAMA PRé-MENOPAUSAL, E, MéTODOS DE PREVENçãO OU DE CURA DE DOENçAS, OU UM MéTODO DE CONTRACEPçãO, DE PRODUçãO DA COMPOSIçãO DE LIBERAçãO CONTROLADA, E PARA A PREVENçãO DA RECORRêNCIA DE CâNCER DE MAMA APóS A OPERAçãO DE CâNCER DE MAMA PRé-MENOPAUSAL". é proporcionada uma composição de liberação controlada contendo uma substância fisiologicamente ativa em conteúdo elevado, que suprime a liberação excessiva inicial, e alcança uma velocidade de liberação estável durante um período de tempo longo. Uma composição de liberação controlada compreendendo: (1) uma substância fisiologicamente ativa ou um seu sal em uma quantidade de cerca de 14% (p/p) a cerca de 24% (p/p) baseada no peso da composíção total, (2) ácido hidróxi-naftóico selecionado do grupo consistindo de ácido 3-hidróxi-2-naftóico e ácido 1-hidróxi-2-naftóico ou seu sal, e (3) um polímero de ácido lático ou seu sal possuindo um peso molecular ponderal médio de 15.000 a 50.000 no qual o conteúdo de polímeros possuindo pesos moleculares de 5.000 ou menores é de cerca de 5% em peso ou menos, na qual a razão molar de citado ácido hidróxi-naftóico ou seu sal para a citada substância fisiologicamente ativa ou seu sal é de 3:4 a 4:3.
BR0210561-6 2001-06-29 2002-06-28 composição de liberação controlada compreendendo polímero de ácido lático e um derivado de lh-rh, método de produção da mesma, e, medicamento. BRPI0210561B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2001-199484 2001-06-29
JP2001199484 2001-06-29
JP2001-340993 2001-11-06
JP2001340993 2001-11-06
PCT/JP2002/006527 WO2003002092A2 (en) 2001-06-29 2002-06-28 Controlled release composition comprising lactic acid polymer and hydroxynaphthoic acid, and method of producing the same

Publications (3)

Publication Number Publication Date
BR0210561A true BR0210561A (pt) 2004-06-22
BRPI0210561B1 BRPI0210561B1 (pt) 2018-08-14
BRPI0210561B8 BRPI0210561B8 (pt) 2021-05-25

Family

ID=26617910

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0210561-6 BRPI0210561B8 (pt) 2001-06-29 2002-06-28 composição de liberação controlada compreendendo polímero de ácido lático e um derivado de lh-rh, método de produção da mesma, e, medicamento.

Country Status (34)

Country Link
US (4) US7429559B2 (pt)
EP (3) EP1330293B2 (pt)
JP (5) JP2003206240A (pt)
KR (2) KR100916173B1 (pt)
CN (3) CN1292796C (pt)
AR (2) AR034641A1 (pt)
AT (3) ATE509668T1 (pt)
AU (2) AU2002311631B2 (pt)
BR (1) BRPI0210561B8 (pt)
CA (1) CA2455392C (pt)
CO (1) CO5540367A2 (pt)
CR (1) CR11283A (pt)
CY (2) CY1105071T1 (pt)
CZ (1) CZ306327B6 (pt)
DE (2) DE60225481T2 (pt)
DK (2) DK1949936T3 (pt)
ES (2) ES2263788T5 (pt)
HK (1) HK1056332A1 (pt)
HU (1) HU230351B1 (pt)
IL (3) IL159059A0 (pt)
MX (1) MXPA03011456A (pt)
MY (1) MY142066A (pt)
NO (1) NO331883B1 (pt)
NZ (2) NZ529969A (pt)
PE (1) PE20030066A1 (pt)
PL (1) PL204903B1 (pt)
PT (2) PT1949936E (pt)
RU (1) RU2301661C2 (pt)
SG (1) SG180015A1 (pt)
SI (1) SI1949936T1 (pt)
SK (1) SK287577B6 (pt)
TW (2) TWI332407B (pt)
WO (1) WO2003002092A2 (pt)
ZA (1) ZA200309152B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1048301A4 (en) 1998-01-16 2005-03-09 Takeda Chemical Industries Ltd COMPOSITIONS WITH DELAYED ACTIVE INGREDIENTS, PROCESS FOR THEIR PREPARATION AND THEIR USE
TWI225416B (en) * 2001-06-29 2004-12-21 Takeda Chemical Industries Ltd Sustained-release composition and process for producing the same
AR034641A1 (es) * 2001-06-29 2004-03-03 Takeda Pharmaceutical Composicion de liberacion controlada y metodo para producirla
EP1532985B1 (en) * 2002-06-25 2016-10-12 Takeda Pharmaceutical Company Limited Process for producing a sustained-release composition
CN101410174B (zh) 2003-04-10 2011-04-06 Pr药品有限公司 一种用于生产基于乳化的微观粒子的方法
US20070207211A1 (en) * 2003-04-10 2007-09-06 Pr Pharmaceuticals, Inc. Emulsion-based microparticles and methods for the production thereof
EP1651136B1 (en) * 2003-07-15 2017-03-08 Evonik Corporation Method for the preparation of controlled release formulations
CA2533592C (en) * 2003-07-23 2015-11-10 Pr Pharmaceuticals, Inc. Controlled release compositions
TW200529890A (en) * 2004-02-10 2005-09-16 Takeda Pharmaceutical Sustained-release preparations
TW200613012A (en) * 2004-07-02 2006-05-01 Takeda Pharmaceuticals Co Sustained-release composition, process for producing the same and use of the same
US20060251581A1 (en) * 2005-05-09 2006-11-09 Mcintyre Jon T Method for treatment of uterine fibroid tumors
US20070149457A1 (en) * 2005-12-13 2007-06-28 Byron Rubin Stable solid forms of enterostatin
AU2007207618B2 (en) 2006-01-18 2011-03-24 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical compositions with enhanced stability
US7858663B1 (en) * 2007-10-31 2010-12-28 Pisgah Laboratories, Inc. Physical and chemical properties of thyroid hormone organic acid addition salts
TWI481424B (zh) 2006-12-18 2015-04-21 Takeda Pharmaceutical 緩釋性組成物及其製法
US20110319987A1 (en) * 2009-05-20 2011-12-29 Arsenal Medical Medical implant
KR101811797B1 (ko) * 2013-04-03 2017-12-22 동국제약 주식회사 도네페질을 포함하는 비경구투여용 약제학적 조성물
JP6564369B2 (ja) 2013-12-09 2019-08-21 デュレクト コーポレイション 薬学的活性剤複合体、ポリマー複合体、ならびにこれらを伴う組成物及び方法
CN103751851A (zh) * 2014-01-17 2014-04-30 东华大学 一种无机/有机多药物控释复合纳米纤维支架的制备方法
KR101558083B1 (ko) * 2014-04-07 2015-10-07 에스케이케미칼주식회사 약물함유 고분자미립구 제조방법
WO2015158823A1 (de) 2014-04-16 2015-10-22 Veyx-Pharma Gmbh Veterinärpharmazeutische zusammensetzung und deren verwendung
US10787920B2 (en) 2016-10-12 2020-09-29 General Electric Company Turbine engine inducer assembly
KR102089737B1 (ko) * 2017-11-01 2020-03-16 한국화학연구원 에씨탈로프람을 함유한 미립구형 서방출 주사제 및 그의 제조방법

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3297033A (en) * 1963-10-31 1967-01-10 American Cyanamid Co Surgical sutures
US3565869A (en) * 1968-12-23 1971-02-23 American Cyanamid Co Extrudable and stretchable polyglycolic acid and process for preparing same
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3755558A (en) * 1971-02-23 1973-08-28 Du Pont Polylactide drug mixtures for topical application atelet aggregation
US3839297A (en) * 1971-11-22 1974-10-01 Ethicon Inc Use of stannous octoate catalyst in the manufacture of l(-)lactide-glycolide copolymer sutures
US3912692A (en) * 1973-05-03 1975-10-14 American Cyanamid Co Process for polymerizing a substantially pure glycolide composition
US3890283A (en) * 1973-06-04 1975-06-17 American Cyanamid Co Process for post-polymerizing polyglycolic acid
US4258063A (en) 1978-06-23 1981-03-24 Henkel Corporation Self-emulsifying cosmetic base
US4249531A (en) * 1979-07-05 1981-02-10 Alza Corporation Bioerodible system for delivering drug manufactured from poly(carboxylic acid)
US4273920A (en) * 1979-09-12 1981-06-16 Eli Lilly And Company Polymerization process and product
PH19942A (en) 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4479911A (en) * 1982-01-28 1984-10-30 Sandoz, Inc. Process for preparation of microspheres and modification of release rate of core material
US4605730A (en) * 1982-10-01 1986-08-12 Ethicon, Inc. Surgical articles of copolymers of glycolide and ε-caprolactone and methods of producing the same
US4539981A (en) * 1982-11-08 1985-09-10 Johnson & Johnson Products, Inc. Absorbable bone fixation device
FR2537980B1 (fr) * 1982-12-17 1986-12-19 Sandoz Sa Derives d'acides hydroxycarboxyliques oligomeres, leur preparation et leur utilisation
CH656884A5 (de) 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
JPH0678425B2 (ja) 1984-07-06 1994-10-05 和光純薬工業株式会社 重合体の新規製造法
CA1236641A (en) * 1984-07-06 1988-05-10 Motoaki Tanaka Copolymer of lactic acid and glycolic acid and method for producing same
DE3678308D1 (de) 1985-02-07 1991-05-02 Takeda Chemical Industries Ltd Verfahren zur herstellung von mikrokapseln.
JP2551756B2 (ja) * 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
CA2040141C (en) * 1990-04-13 2002-05-14 Minoru Yamada Biodegradable high-molecular polymers, production and use therof
JP3277342B2 (ja) 1992-09-02 2002-04-22 武田薬品工業株式会社 徐放性マイクロカプセルの製造法
US5353086A (en) * 1993-05-03 1994-10-04 Eastman Kodak Company Textured surface with canted channels for an automatic tray processor
DE4342092B4 (de) * 1993-12-09 2007-01-11 Zentaris Gmbh Langwirkende Injektionssuspension und Verfahren zur Herstellung
ATE178789T1 (de) * 1994-02-21 1999-04-15 Takeda Chemical Industries Ltd Polyester matrix für eine pharmazeutische zusammensetzung mit verzögerter freigabe
JP3490171B2 (ja) 1994-02-21 2004-01-26 武田薬品工業株式会社 生体内分解性ポリマーの末端カルボキシル基におけるエステル
US5763513A (en) * 1994-05-19 1998-06-09 Mitsui Toatsu Chemicals, Inc. L-lactic acid polymer composition, molded product and film
JPH08259460A (ja) * 1995-01-23 1996-10-08 Takeda Chem Ind Ltd 徐放性製剤の製造法
JP3902272B2 (ja) * 1995-09-04 2007-04-04 武田薬品工業株式会社 徐放性製剤の製造法
US5922662A (en) * 1996-08-07 1999-07-13 Colgate Palmolive Company High foaming nonionic surfactant based liquid detergent
ATE272394T1 (de) * 1996-10-31 2004-08-15 Takeda Chemical Industries Ltd Zubereitung mit verzögerter freisetzung
WO1998032423A1 (en) 1997-01-29 1998-07-30 Takeda Chemical Industries, Ltd. Sustained-release microspheres, their production and use
JPH10273447A (ja) * 1997-01-29 1998-10-13 Takeda Chem Ind Ltd 徐放性マイクロスフィア、その製造法および用途
JPH11269094A (ja) 1998-01-16 1999-10-05 Takeda Chem Ind Ltd 徐放性組成物、その製造法および用途
EP1048301A4 (en) 1998-01-16 2005-03-09 Takeda Chemical Industries Ltd COMPOSITIONS WITH DELAYED ACTIVE INGREDIENTS, PROCESS FOR THEIR PREPARATION AND THEIR USE
US6114495A (en) * 1998-04-01 2000-09-05 Cargill Incorporated Lactic acid residue containing polymer composition and product having improved stability, and method for preparation and use thereof
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
KR100584634B1 (ko) * 1998-12-15 2006-05-30 다케다 야쿠힌 고교 가부시키가이샤 폴리머의 제조방법
JP2000238051A (ja) † 1999-02-23 2000-09-05 Kansei Corp 表皮シートの発泡成形型へのセッティング方法
JP2001081043A (ja) * 1999-07-15 2001-03-27 Takeda Chem Ind Ltd 徐放性組成物、その製造法および用途
DE60034568T2 (de) 1999-07-15 2008-01-03 Takeda Pharmaceutical Co. Ltd. Zusammensetzungen mit verzögerter freigabe, verfahren zu deren herstellung und verwendung
JP3837607B2 (ja) † 2000-05-29 2006-10-25 Ｔｃｍ株式会社 マスト用溶接位置決め治具
ES2577389T3 (es) † 2000-08-07 2016-07-14 Wako Pure Chemical Industries, Ltd. Polímero de ácido láctico y procedimiento para su producción
WO2002043766A1 (fr) * 2000-11-29 2002-06-06 Takeda Chemical Industries, Ltd. Compositions medicinales et leur procede de preparation
WO2002047722A1 (fr) * 2000-12-15 2002-06-20 Takeda Chemical Industries, Ltd. Compositions medicinales agoniste ou antagoniste de la gonadoliberine non peptidyl, methode de production et utilisation desdites compositions
AR034641A1 (es) * 2001-06-29 2004-03-03 Takeda Pharmaceutical Composicion de liberacion controlada y metodo para producirla

Also Published As

Publication number Publication date
KR20090020708A (ko) 2009-02-26
AU2006246508B2 (en) 2008-09-04
SK15602003A3 (sk) 2004-06-08
DK1330293T3 (da) 2006-09-11
US20110166084A1 (en) 2011-07-07
AU2002311631B2 (en) 2007-02-08
ZA200309152B (en) 2005-01-26
AR098261A2 (es) 2016-05-18
EP1491236A1 (en) 2004-12-29
DE60211464T2 (de) 2006-09-07
DK1949936T3 (da) 2011-08-15
AU2006246508A1 (en) 2006-12-21
HUP0400378A3 (en) 2010-01-28
KR100916173B1 (ko) 2009-09-08
JP2010189427A (ja) 2010-09-02
BRPI0210561B1 (pt) 2018-08-14
JP2004238400A (ja) 2004-08-26
SK287577B6 (sk) 2011-03-04
KR20040018402A (ko) 2004-03-03
CN1868458A (zh) 2006-11-29
JP4819173B2 (ja) 2011-11-24
EP1949936B1 (en) 2011-05-18
PT1330293E (pt) 2006-08-31
DK1330293T4 (da) 2011-01-10
EP1949936A2 (en) 2008-07-30
JP2009167203A (ja) 2009-07-30
US20120283187A1 (en) 2012-11-08
ES2366677T3 (es) 2011-10-24
ATE509668T1 (de) 2011-06-15
HK1056332A1 (en) 2004-02-13
EP1949936A3 (en) 2008-10-08
CY1111708T1 (el) 2015-10-07
SI1949936T1 (sl) 2011-08-31
ES2263788T5 (es) 2011-02-22
NO20035738L (no) 2004-02-27
BRPI0210561B8 (pt) 2021-05-25
WO2003002092A3 (en) 2003-04-10
CZ20033493A3 (cs) 2004-08-18
CN100348265C (zh) 2007-11-14
RU2301661C2 (ru) 2007-06-27
JP4819172B2 (ja) 2011-11-24
PT1949936E (pt) 2011-07-12
SG180015A1 (en) 2012-05-30
EP1330293B1 (en) 2006-05-17
HUP0400378A2 (hu) 2004-12-28
IL159059A0 (en) 2004-05-12
CN1292796C (zh) 2007-01-03
US8067030B2 (en) 2011-11-29
NO20035738D0 (no) 2003-12-19
MY142066A (en) 2010-08-30
CA2455392A1 (en) 2003-01-09
US20090005318A1 (en) 2009-01-01
DE60225481D1 (de) 2008-04-17
CO5540367A2 (es) 2005-07-29
NO331883B1 (no) 2012-04-23
NZ541884A (en) 2007-01-26
DE60225481T2 (de) 2009-02-26
WO2003002092A2 (en) 2003-01-09
CZ306327B6 (cs) 2016-12-07
CR11283A (es) 2010-05-31
EP1491236B1 (en) 2008-03-05
IL186782A0 (en) 2008-02-09
TWI332407B (en) 2010-11-01
PL204903B1 (pl) 2010-02-26
US8815801B2 (en) 2014-08-26
CN1535168A (zh) 2004-10-06
TW200526267A (en) 2005-08-16
US7429559B2 (en) 2008-09-30
CN1724066A (zh) 2006-01-25
ATE326264T1 (de) 2006-06-15
US20030134800A1 (en) 2003-07-17
EP1330293A2 (en) 2003-07-30
RU2004102507A (ru) 2005-03-10
AR034641A1 (es) 2004-03-03
ATE387937T1 (de) 2008-03-15
MXPA03011456A (es) 2004-07-01
NZ529969A (en) 2005-10-28
PE20030066A1 (es) 2003-03-20
CN100577206C (zh) 2010-01-06
EP1330293B2 (en) 2010-10-27
PL367518A1 (en) 2005-02-21
DE60211464D1 (de) 2006-06-22
ES2263788T3 (es) 2006-12-16
JP2003206240A (ja) 2003-07-22
KR100961413B1 (ko) 2010-06-09
DE60211464T3 (de) 2011-03-17
CA2455392C (en) 2011-11-22
IL159059A (en) 2011-06-30
JP2010189428A (ja) 2010-09-02
HU230351B1 (hu) 2016-02-29
US8246987B2 (en) 2012-08-21
CY1105071T1 (el) 2010-03-03

Similar Documents

Publication Publication Date Title
BR0210561A (pt) Composição de liberação controlada, medicamento, droga para a prevenção ou cura para doenças, ou um agente contraceptivo, agente para a prevenção da recorrência de câncer de mama após a operação de câncer de mama pré-menopausal, e, métodos de prevenção ou de cura de doenças, ou um método de contracepção, de produção da composição de liberação controlada, e para a prevenção da recorrência de câncer de mama após a operação de câncer de mama pré-menopausal
US4650665A (en) Controlled release of pharmacologically active agents from an absorbable biologically compatible putty-like composition
US4568536A (en) Controlled release of pharmacologically active agents from an absorbable biologically compatible putty-like composition
EP2564847B1 (en) Pharmaceutical composition for improving solubility of prasugrel and its preparation method
JP2001524094A (ja) 粘膜表面への改良された薬物供給
CA2049668C (en) Bioerodible implants
AU698881B2 (en) Compositions for treatment of chronic inflammatory diseases
BR0210572A (pt) Composição de liberação prolongada, processo para produzir a mesma, comosição farmacêutica, agentes e método para prevenir ou tratar doenças, ou um contraceptivo, e para prevenir a recorrência de câncer de mama após a operação para câncer de mama pré-menopausal, processo para produzir um polìmero de ácido lático - ácido glicólico, polìmero de ácido lático - ácido glicólico, uso do mesmo ou de seu sal, e, microsfera
US20020037917A1 (en) Treatment of cancer using lipoic acid in combination with ascorbic acid
BR0012400A (pt) Composição de liberação continuada, método para produzir composição de liberação continuada, medicamento, e, agente profilático ou terapeutico
CA2253980A1 (en) Locally administrable, biodegradable and sustained-release pharmaceutical composition for periodontitis and process for preparation thereof
CO5060477A1 (es) Forma de dosificacion de nefazodona
DE69519685T2 (de) Oral anzuwendende arzneizubereitung mit verzögerter wirkstoffabgabe
JPH08253412A (ja) ポリエチレングリコールのためのゲル化剤
Radwan-Pragłowska et al. ZnO nanorods functionalized with chitosan hydrogels crosslinked with azelaic acid for transdermal drug delivery
JP2000516614A (ja) 製薬適用用組成物
ES2158101T3 (es) Formulaciones farmaceuticas efervescentes que contienen microcapsulas biodegradables de liberacion controlada.
KR20050000506A (ko) 온도 반응성 전달계
NZ510563A (en) Multiple unit controlled food effect-independent release pharmaceutical preparations and method for preparing the same
MY130098A (en) Local drug delivery film for periodontal treatment
RU2369379C2 (ru) Нетаблетированные жевательные дозировочные формы для индивидуального введения
US4491575A (en) Compressed products with retarded release of active substance, a process for their preparation and a process for the long-term administration of medicaments
IL106743A (en) Tablets with enhanced bioavailability of claudonic acid
WO2010123900A1 (en) Polymeric carrier systems with multiple burst release potential
CN100488514C (zh) 伊维菌素微球缓释固体剂

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)

Free format text: ALTERADO DE: TAKEDA CHEMICAL INDUSTRIES, LTD.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 9/16 (2006.01), A61P 5/06 (2006.01), A61P 15/

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/06/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B15V Prolongation of time limit allowed
B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2728 DE 18/04/2023 POR TER SIDO INDEVIDA.

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 28/06/2022